Article info
PDFInflammatory bowel disease
Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease
- Correspondence to:
Dr D W Hommes
Department Gastroenterology and Hepatology, Academic Medical Centre, C2-111, Meibergdreef 9 1105 AZ, Amsterdam, the Netherlands; d.w.hommes{at}amc.uva.nl
Citation
Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease
Publication history
- Accepted December 24, 2005
- Revised December 22, 2005
- First published February 28, 2006.
Online issue publication
April 18, 2016
Article Versions
- Previous version (18 April 2016).
- You are viewing the most recent version of this article.
Conflict of interest: DWH is supported by a grant from The Netherlands Organization for Health Research and Development, and is a consultant for Protein Design Labs. GvA is a consultant for Protein Design Labs. SB and TP are employees of Protein Design Labs, Inc. None declared by the other authors.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2006 by Gut